CHU Henri Mondor — Clinical Trial Site

10 Registered trials

7 Currently recruiting

Organisation

CHU Henri Mondor

Location

Créteil Cedex, France

Identifier

ORL-000006071

Address

1 rue Gustave Eiffel, 94010, France

Departments

Hématologie clinique
Hematology
Nephrology
Neurology
Oncologie Médicale
Oncology
Service d'immunologie clinique et de maladies infectieuses
Service of Clinical Hematology
Unité Hématopathies Lymphoïdes
Unité Hémopathies Lymphoïdes

Clinical trials at this site (10)

Search interface

PTX3 genetically stratified randomized double-blinded allocation event-driven clinical trial for antifungal prophylaxis in patients with acu… Pending

2024-517211-79-00 Antifungal prophylaxis in patients with acute myeloid l 6
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Pending

2025-521113-13-00 Early Parkinson’s Disease 10
FILO-AML-01-MIVONU A single arm phase II study investigating the efficacy and safety of the addition of ivosidenib to oral azacitidine (Onur… Pending

2025-521322-14-00 Patients over 55 with Acute Myeloid Leukemia (AML) and 4
An Experimental Medicine multicenter Trial to evaluate the safety and immunogenicity of experimental versus authorized SARS-CoV-2 vaccine ca… Recruiting

2025-520652-28-00 healthy participants 1 2026-05-04
FILOWM4-WaZaBi: "Open label phase 2 study evaluating the efficacy and tolerance of a zanubrutinib and BGB-11417 combination in patients prev… Recruiting

2023-505781-28-00 Patients with Waldenstrom macroglobulinemia and have re 4 2026-01-20
IFM2024-06 : A multi-center, open-label, phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as p… Recruiting

2024-517325-43-00 multiple myeloma 4 2025-06-19
A Phase 3 Study of a GPRC5D-directed CAR T Cell Therapy in Participants with Relapsed or Refractory Multiple Myeloma and Exposed to Lenalido… Recruiting

2024-515279-37-00 Relapsed or Refractory and Lenalidomide exposed Multipl 5 2025-04-17
Dose individualization of chemotherapy in patients with gastrointestinal cancers lacking a specific liver enzyme Recruiting

2023-509963-25-00 Fluoropyrimidine (FP)-naive patients with gastrointesti 4 2025-01-17
Study of Artificial Intelligence-based Personalized Rituximab Treatment Protocol in Membranous nephropathy - iRITUX Recruiting

2024-510718-34-00 Membranous nephropathy 11 2024-11-29
PRODIGE 98- AMPIRINOX : Randomized, multicenter, Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or ge… Recruiting

2024-511070-68-01 Ampullary adenocarcinoma 5 2024-09-24